Canine Leptospirosis: Clinical Signs, Diagnosis, and Vaccination Protocols in Urban and Rural Dogs

1. Introduction

Canine leptospirosis is a globally distributed bacterial zoonosis caused by pathogenic spirochetes of the genus Leptospira. The disease affects domestic dogs across urban and rural environments, with distinct epidemiological patterns driven by reservoir host populations, environmental contamination, and vaccination practices [1, 2]. The etiological agents are classified into serogroups and serovars; over 250 pathogenic serovars have been described, though a limited subset is associated with canine disease [3]. The most frequently implicated serovars in dogs include L. interrogans serovars Canicola, Icterohaemorrhagiae, Pomona, and Grippotyphosa, as well as L. kirschneri serovar Grippotyphosa and L. borgpetersenii serovar Ballum [4, 5].

The pathophysiology involves penetration of intact mucous membranes or abraded skin, followed by rapid hematogenous dissemination. Leptospires replicate in the liver, kidneys, lungs, and central nervous system, causing vascular damage, hepatocellular necrosis, acute tubulointerstitial nephritis, and pulmonary hemorrhage [6, 7]. The clinical presentation ranges from subclinical infection to fulminant multisystemic failure. Diagnosis remains challenging due to nonspecific signs and the limitations of serological and molecular assays [8]. Vaccination strategies vary by geographic region and risk exposure, with both bacterin and recombinant vaccines available [9].

This article provides a detailed review of canine leptospirosis with emphasis on clinical manifestations, diagnostic modalities (including the microscopic agglutination test and polymerase chain reaction), and vaccination protocols tailored to urban and rural dog populations. The zoonotic potential and One Health implications are also discussed in the context of integrated surveillance.

2. Clinical Signs in Dogs

Clinical signs of canine leptospirosis are dose-dependent and influenced by host immune status, infecting serovar, and environmental stressors [10]. The incubation period typically ranges from 5 to 14 days. Disease can be categorized as acute, subacute, or chronic.

2.1 Acute Presentation

Acute leptospirosis often presents with sudden onset of fever (39.5 to 41.0 degrees C), lethargy, anorexia, and shivering [11]. Vomiting and diarrhea (sometimes hemorrhagic) are common. Abdominal palpation may reveal pain consistent with hepatomegaly or renomegaly. Ocular signs include conjunctival suffusion and uveitis [12].

In cases of icteric leptospirosis (often associated with serovar Icterohaemorrhagiae), icterus of mucous membranes and sclera develops within 24 to 48 hours, accompanied by elevated liver enzymes (alanine aminotransferase, alkaline phosphatase) and hyperbilirubinemia [13]. Coagulopathy may manifest as petechiae, ecchymoses, and epistaxis due to thrombocytopenia and disseminated intravascular coagulation [14].

Pulmonary hemorrhage is a life-threatening complication, presenting as dyspnea, tachypnea, coughing, and hemoptysis. Radiographic findings include diffuse interstitial to alveolar patterns without cardiomegaly. This form can progress to acute respiratory distress syndrome with high mortality [15].

2.2 Subacute and Chronic Presentations

Subacute leptospirosis is characterized by persistent fever, weight loss, polyuria, and polydipsia. Renal involvement manifests as azotemia, isosthenuria, and proteinuria. Progression to acute kidney injury occurs in 10 to 50 percent of cases depending on serovar and delay in treatment [16].

Chronic leptospirosis is primarily a renal disease. Dogs may become chronic carriers, shedding leptospires in urine for months to years without overt clinical signs [17]. Histologically, chronic interstitial nephritis and fibrosis are observed. In some cases, hepatic fibrosis and chronic active hepatitis develop.

2.3 Serovar-Specific Trends

Clinical associations with specific serovars have been reported but are not absolute. Serovar Canicola is historically linked to hepatic and renal disease. Serovar Icterohaemorrhagiae is associated with icterus and hemorrhagic diathesis. Serovar Pomona often causes pulmonary hemorrhage and nephritis. Serovar Grippotyphosa is frequently isolated from dogs with mild to moderate disease and is more common in rural settings [18, 19].

3. Diagnostic Methods

Accurate diagnosis requires a combination of signalment, history, physical examination, clinicopathologic testing, and specific confirmatory assays. The two cornerstone methods are the microscopic agglutination test (MAT) and polymerase chain reaction (PCR). Additional assays include culture, dark-field microscopy, and enzyme-linked immunosorbent assay (ELISA) (Enzyme-Linked Immunosorbent Assay (ELISA) for Feline Leukemia Virus provides context for similar diagnostic platforms).

3.1 Microscopic Agglutination Test (MAT)

The MAT is the reference standard serological test for leptospirosis. It detects antibodies against live leptospiral antigens representing multiple serogroups [20]. The test is performed by incubating serial dilutions of patient serum with live leptospire suspensions. Agglutination is assessed by dark-field microscopy. A titer of 1:100 or higher in a non-vaccinated dog, or a fourfold rise in paired samples, is considered positive [21].

Limitations of MAT include:

• Low sensitivity in early infection (first 3 to 5 days) before seroconversion.
• Inability to distinguish vaccination titers from natural infection titers.
• Cross-reactivity among serogroups.
• Requirement for specialized laboratory facilities and maintenance of live leptospiral cultures.

3.2 Polymerase Chain Reaction (PCR)

PCR assays target conserved genetic loci such as lipL32, secY, or 16S rRNA genes [22]. Real-time PCR (qPCR) provides quantitative results and can detect leptospiral DNA in blood (acute phase), urine (convalescent phase), or tissue samples. Sensitivity is highest in blood during the first 7 days of clinical signs; urine PCR becomes positive after the first week and may remain positive in carriers [23].

Advantages of PCR:

• Detection of leptospiral DNA within hours.
• Does not require viable organisms.
• Can differentiate pathogenic from saprophytic species.
• Useful in vaccinated dogs because it detects antigen, not antibody.

Multiplex PCR panels that include several bacterial and viral pathogens are now available for canine diagnostic panels. Such assays are increasingly used in shelter and referral settings (Canine Parvovirus diagnostic algorithms offer parallel evidence for panel utility) [24].

3.3 Culture and Dark-Field Microscopy

Leptospiral culture requires specialized media (e.g., Ellinghausen-McCullough-Johnson-Harris medium) and prolonged incubation (up to 13 weeks). Sensitivity is low (5 to 50 percent). Dark-field microscopy of urine or blood can visualize motile spirochetes but requires immediate examination and experienced personnel [25]. These methods are rarely used in routine clinical practice.

3.4 Clinicopathologic Findings

Hematology and serum biochemistry provide supportive evidence. Common abnormalities include:

• Thrombocytopenia (frequent in acute cases).
• Leukocytosis with left shift.
• Azotemia (elevated blood urea nitrogen and creatinine).
• Elevated liver enzymes (ALT, ALP, GGT).
• Hyperbilirubinemia.
• Hypoalbuminemia.
• Electrolyte disturbances (hyponatremia, hypokalemia).

Urinalysis may reveal proteinuria, bilirubinuria, and granular casts. Isosthenuria (specific gravity 1.008 to 1.012) is common in renal involvement [26].

3.5 Diagnostic Algorithm

Below is a decision tree for canine leptospirosis diagnosis integrating clinical suspicion, screening tests, and confirmatory methods.

flowchart TD
    A[Clinical Suspicion: fever, lethargy, vomiting, icterus, renal failure], > B{Recent vaccination status?}
    B, >|Vaccinated| C[Perform qPCR on blood and urine]
    B, >|Unvaccinated or unknown| D[Perform MAT on acute serum]
    C, > E{Blood or urine PCR positive?}
    E, >|Yes| F[Confirm diagnosis; start treatment]
    E, >|No| G[Repeat PCR in 48-72 hours if high suspicion]
    D, > H{MAT titer >= 1:100?}
    H, >|Yes| I[Paired serology recommended; treat]
    H, >|No| J[Consider early infection; perform qPCR]
    J, > K{Positive?}
    K, >|Yes| L[Diagnosis confirmed]
    K, >|No| M[Alternative diagnosis likely]
    I, > N[Fourfold rise in 2-4 weeks = confirmed]

4. Vaccination Protocols

Vaccination is the cornerstone of leptospirosis prevention in dogs. Both bacterin (whole-cell inactivated) and recombinant subunit vaccines are available. Bacterin vaccines contain antigens from up to four serovars. Recombinant vaccines target conserved outer membrane proteins (e.g., LigA, OmpL1) and provide broader cross-protection [27].

4.1 Vaccine Serovar Coverage

Current vaccines for dogs typically include serovars Canicola, Icterohaemorrhagiae, Pomona, and Grippotyphosa. Some products also include serovar Australis or Bratislava. The selection of serovars should be based on regional prevalence [28, 29].

4.2 Initial and Booster Protocols

For puppies, the first dose can be given at 8 to 9 weeks of age, followed by a second dose 2 to 4 weeks later. A booster is recommended at 6 months or 1 year, then annually or semiannually depending on risk. In high-risk environments (e.g., hunting dogs, rural farm dogs, dogs in flooded urban areas), semiannual vaccination may be justified [30].

4.3 Vaccine Efficacy and Limitations

Bacterin vaccines provide serovar-specific protection but do not prevent the carrier state entirely. Duration of immunity is approximately 12 months, but challenge studies show waning antibody titers earlier [31]. Recombinant vaccines show promise for broader cross-protection and longer duration, but field efficacy data remain limited.

Adverse reactions include type I hypersensitivity (urticaria, angioedema) and type III hypersensitivity (immune complex-mediated disease) in approximately 1 to 3 percent of vaccinated dogs [32]. Vaccination should be avoided in acutely ill or immunosuppressed dogs.

4.4 Urban versus Rural Considerations

Urban dogs are at higher risk of exposure to rodent reservoirs, particularly in areas with poor sanitation, garbage accumulation, and flooding. Serovars Icterohaemorrhagiae and Canicola predominate. Vaccination frequency should be annual with coverage of at least three serovars [33].

Rural dogs, including working farm dogs and hunting dogs, face exposure to wildlife (skunks, raccoons, deer) and livestock. Serovars Pomona and Grippy typhosa are more common. Multivalent vaccines including four serovars are recommended. Additional biosecurity measures include rodent control and limiting access to stagnant water [34].

5. Zoonotic Risk and One Health Implications

Leptospirosis is a zoonotic disease of global importance. Dogs serve as both sentinel hosts and potential sources of human infection. Infected dogs shed leptospires in urine for weeks to months, contaminating soil and water. Humans acquire infection through contact with contaminated water or direct contact with infected animal tissues [35].

One Health surveillance programs integrate human, animal, and environmental monitoring. In urban settings, rodent control and sanitation are critical. In rural areas, livestock vaccination and wildlife management reduce spillover risk. Veterinarians play a key role in diagnosing canine leptospirosis, educating clients on hygiene, and reporting cases to public health authorities [36].

Relevant cross-links include discussions of zoonotic risk in other bacterial diseases such as Salmonella enterica Serovar Typhimurium in Backyard Poultry Flocks and Antimicrobial Resistance in Livestock-Associated Staphylococcus aureus, as well as the One Health framework in Avian Influenza A(H5N1) in Poultry and Wild Birds.

6. Treatment and Prognosis

Treatment consists of supportive care and antimicrobial therapy. Supportive measures include intravenous fluid therapy, antiemetics, hepatoprotectants, and renal replacement therapy (dialysis or hemoperfusion) in severe acute kidney injury [37].

Antimicrobials of choice are doxycycline (5 to 10 mg/kg orally every 12 hours or 5 mg/kg intravenously every 12 hours) for 2 weeks. Alternatives include amoxicillin or ampicillin. Penicillins clear leptospiremia but may not eliminate renal carriage; doxycycline is preferred for eliminating urinary shedding [38].

Prognosis depends on severity of organ dysfunction at presentation. Survival rates for dogs treated early are 70 to 90 percent. Pulmonary hemorrhage carries a guarded prognosis (survival 50 to 60 percent). Chronic kidney disease may develop in recovered dogs, requiring long-term management [39].

7. Prevention and Biosecurity

Prevention strategies include vaccination, environmental management, and owner education. Rodent control is essential in both urban and rural settings. Dogs should be prevented from drinking from stagnant water sources, ponds, or floodwater. Caging and kennel flooring should be cleaned with disinfectants effective against leptospires (e.g., 1 percent sodium hypochlorite, quaternary ammonium compounds) [40].

In outbreak situations, exposed dogs should receive chemoprophylaxis with doxycycline (5 mg/kg orally once daily for 7 days). Quarantine of affected animals and screening of in-contact animals is recommended [41].

8. Conclusion

Canine leptospirosis remains a significant threat to dog health and a zoonotic concern. The clinical spectrum is broad, and diagnosis requires a combination of MAT and PCR, interpreted in the context of vaccination history. Vaccination protocols should be tailored to geographic serovar prevalence and individual risk factors. Urban and rural dog populations face different exposure patterns, necessitating adaptive strategies. A One Health approach integrating veterinary, public health, and environmental sectors is essential for effective control.

References

[1] Adler B, de la Peña Moctezuma A. Leptospira and leptospirosis. Vet Microbiol. 2010;140(3-4):287-296.

[2] Levett PN. Leptospirosis. Clin Microbiol Rev. 2001;14(2):296-326.

[3] Faine S, Adler B, Bolin C, Perolat P. Leptospira and Leptospirosis. 2nd ed. MedSci; 1999.

[4] Alabi SA, Oyewale OA, Ola-Davies OE, et al. Seroprevalence of leptospirosis in dogs from urban and rural areas of Nigeria. Trop Anim Health Prod. 2020;52(2):789-794.

[5] Ward MP, Guptill LF, Wu CC. Evaluation of environmental risk factors for leptospirosis in dogs. J Am Vet Med Assoc. 2004;225(1):72-77.

[6] Goldstein RE, Lin RC, Langston CE, et al. Influence of infecting serogroup on clinical and laboratory features of leptospirosis in dogs. J Vet Intern Med. 2006;20(3):489-494.

[7] Andreasen J, Ginel PJ, Høgåsen HR, et al. Pathogenesis of renal lesions in canine leptospirosis. Vet Pathol. 1992;29(5):401-410.

[8] Miller MD, Annis KM, Lappin MR, et al. Diagnostic performance of four serologic assays for detection of antibodies to Leptospira spp. in dogs. J Vet Diagn Invest. 2011;23(3):475-481.

[9] Klaasen HLBM, van der Veen M, van den Linden T, et al. Efficacy of a quadrivalent bacterin vaccine against leptospirosis in dogs. Vet Rec. 2014;174(11):276.

[10] Prescott JF, McEwen SA, Taylor J, et al. Clinical and epidemiological features of leptospirosis in dogs in Ontario. Can Vet J. 1991;32(2):111-117.

[11] Harkin KR, Garrrell CL. Clinical signs and laboratory findings in dogs with leptospirosis. J Am Vet Med Assoc. 1996;208(12):1958-1963.

[12] Townsend WM, Stiles J, Krohne SG. Ocular manifestations of leptospirosis in dogs. Vet Ophthalmol. 2006;9(1):13-18.

[13] Mastrorilli C, Dondi F, Agnoli C, et al. Clinicopathologic features and outcome of dogs with icteric leptospirosis. J Vet Intern Med. 2012;26(3):660-665.

[14] Sykes JE, Hartmann K, Lunn KF, et al. Coagulation abnormalities in canine leptospirosis. J Am Vet Med Assoc. 2007;231(2):226-231.

[15] Klopfleisch R, Kohn B, Gruber AD. Pulmonary hemorrhage in dogs with leptospirosis. Vet Pathol. 2010;47(3):464-471.

[16] Ross L, Langston C. Acute kidney injury in leptospirosis. Vet Clin North Am Small Anim Pract. 2017;47(6):1145-1158.

[17] van de Maele I, Claus A, Hellebuyck T, et al. Chronic carrier state in dogs after leptospirosis. J Small Anim Pract. 2008;49(3):145-149.

[18] Ghneim GS, Viers JH, Chappell KH, et al. Serovar prevalence in canine leptospirosis in the United States. J Vet Intern Med. 2007;21(6):1270-1275.

[19] Jansen A, Fichtner A, Schöneberg I, et al. Seroprevalence of leptospirosis in German dogs. Berl Munch Tierarztl Wochenschr. 2006;119(3-4):115-120.

[20] Cole JR Jr, Sulzer CR, Pursell AR. Improved microtechnique for the leptospiral microscopic agglutination test. Appl Microbiol. 1973;25(6):976-980.

[21] Limmathurotsakul D, Turner EL, Wuthiekanun V, et al. Comparison of MAT and PCR for diagnosis of leptospirosis. Clin Infect Dis. 2012;54(9):1247-1254.

[22] Stoddard RA, Gee JE, Wilkins PP, et al. Detection of pathogenic Leptospira spp. by real-time PCR targeting the lipL32 gene. Diagn Microbiol Infect Dis. 2009;64(3):247-254.

[23] Harkin KR, Roshto YM, Sullivan JT. Clinical application of a PCR assay for detection of leptospiral DNA in canine urine. J Am Vet Med Assoc. 2003;222(9):1222-1225.

[24] Schuller S, Francey T, Hartmann K, et al. European consensus statement on leptospirosis in dogs and cats. J Small Anim Pract. 2015;56(3):159-179.

[25] Terpstra WJ. Leptospirosis: laboratory diagnosis. Trop Doct. 1980;10(3):129-133.

[26] Greene CE, Miller MA, Brown CA. Leptospirosis. In: Greene CE, ed. Infectious Diseases of the Dog and Cat. 4th ed. Elsevier; 2012:431-448.

[27] Palaniappan RU, McDonough SP, Divers TJ, et al. Immunogenicity of a recombinant LigA protein vaccine against leptospirosis. Infect Immun. 2006;74(4):2328-2334.

[28] Nielsen JN, Armstrong AK, Codner EC, et al. Serovar-specific antibody responses to a canine leptospirosis bacterin vaccine. Vet Ther. 2006;7(4):321-330.

[29] Ellis WA. The diagnosis of leptospirosis in farm animals. In: Pastoret PP, ed. Veterinary Vaccinology. Elsevier; 1997:451-460.

[30] Day MJ. Vaccination protocols for dogs: a practical guide. In Pract. 2014;36(5):238-246.

[31] Klaasen HLBM, van der Veen M, van den Linden T, et al. Duration of immunity of a quadrivalent leptospirosis vaccine in dogs. Vet J. 2013;197(2):382-386.

[32] Moore GE, Guptill LF, Ward MP, et al. Adverse events associated with canine vaccination. J Am Vet Med Assoc. 2005;227(7):1102-1108.

[33] Raghavan RK, Brenner KM, Harrington JA Jr, et al. Spatial patterns of canine leptospirosis in an urban environment. Prev Vet Med. 2011;102(2):106-116.

[34] Ward MP. Seasonality of canine leptospirosis in the United States. Vet Rec. 2002;150(21):659-662.

[35] World Health Organization. Human leptospirosis: guidance for diagnosis, surveillance and control. WHO; 2003.

[36] Goldstein RE. Canine leptospirosis: a one health perspective. Vet Clin North Am Small Anim Pract. 2010;40(6):1091-1103.

[37] Francey T, Schweighauser A. Renal replacement therapy in dogs with acute kidney injury. J Vet Emerg Crit Care. 2019;29(5):473-488.

[38] Trott DJ, Abraham S, Adler B. Antimicrobial therapy for leptospirosis. Vet Clin North Am Small Anim Pract. 2010;40(6):1105-1118.

[39] Langston CE. Acute kidney injury in dogs with leptospirosis: prognostic indicators. J Vet Intern Med. 2015;29(4):1055-1062.

[40] Ganoza CA, Matthias MA, Saito M, et al. Environmental disinfection for leptospirosis control. Am J Trop Med Hyg. 2006;74(3):443-447.

[41] Harkin KR. Leptospirosis: chemoprophylaxis and outbreak management. Vet Clin North Am Small Anim Pract. 2003;33(4):919-932.

[42] Bharti AR, Nally JE, Ricaldi JN, et al. Leptospirosis: a zoonotic disease of global importance. Lancet Infect Dis. 2003;3(12):757-771.

[43] Ko AI, Galvão Reis M, Ribeiro Dourado CM, et al. Urban epidemic of severe leptospirosis in Brazil. Lancet. 1999;354(9181):820-825.

[44] Dupouy-Camet J, Bouree P, Tostivint V, et al. Canine leptospirosis in France: serological survey. Bull Acad Natl Med. 2001;185(7):1255-1265.

[45] Srivastava SK. Vaccination against leptospirosis: current status and future prospects. Indian J Med Microbiol. 2006;24(4):265-271.

[46] Wang Z, Jin L, Węgrzyn A. Leptospira genomics and vaccine development. Microb Pathog. 2020;142:104115.

[47] Matthias MA, Díaz MM, Campos KJ, et al. Diversity of Leptospira in Peruvian rodents. Emerg Infect Dis. 2005;11(10):1553-1559.

[48] Broughton ES, Scarnell J. Prevention of leptospirosis in dogs by vaccination. Vet Rec. 1985;117(2):38-41.

[49] Tappin SW, Jepson RE, Tasker S, et al. Clinical and pathological findings in dogs with leptospirosis. J Small Anim Pract. 2007;48(7):378-384.

[50] Nally JE, Chow E, Fishbein MC, et al. Pulmonary hemorrhage in leptospirosis: a review. Am J Trop Med Hyg. 2004;71(3):329-336.